ORGANIZATION
Pharmaceutical Research and Manufacturers of America (PhRMA)
trade association · DC
54LDA FILINGS
142LOBBYISTS
0FLY-INS
Federal Lobbying Spend
$53.2M
Total LDA-disclosed spend (in-house + retained) across all reported periods.
Most recent LDA filing posted April 2026.
Topics in Filings
196Policy topics named in LD-2 filings. This org's filings are topical rather than positional — these are the issues it's actively lobbying on, even without a stated verb of position.
PBM reform×63
EPIC Act×57
One Big Beautiful Bill Act×53
PBM Price Transparency and Accountability Act×48
Affordable Prescriptions for Patients Act×46
Inflation Reduction Act×40
Rural Development×38
Drug Competition Enhancement Act×33
Education regard the International Pricing Index×33
Education regarding market based solutions to bring down the cost of drug prices×33
Education regarding the dangers of global counterfeit medications×33
Support for PBM reform×33
Show all 196 topics (+184 more) ▾
Drug pricing×31
Changes to Medicare Part D×28
Drug cost and pricing policy×28
RESTORE Patent Rights Act×28
Supply chain policy×28
Bayh-Dole march-in rights policy×25
Big Savings Act×25
Biopharmaceutical innovation policy×25
Interagency Patent Coordination and Improvement Act×25
Preserve Access to Affordable Generics and Biosimilars Act×25
Stop STALLING Act×25
BIOSECURE Act×24
Most Favored Nation×24
Bipartisan Health Care Act×23
Food and Drug Administration, and Related Agencies Appropriations×23
HELP Copays Act×23
Pharmacy Benefit Manager Reform×23
Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients×20
Trade policies×20
Medicare policies×16
Accountability, and Integrity Now and for the Future×14
AI patent policy×14
Artificial intelligence policy×14
Biopharmaceutical patent and intellectual property policy×14
Biosimilar approval and reimbursement policy×14
Center for Medicare and Medicaid Innovation×14
China outbound investment policy×14
Clinical trial policy×14
Compounding policy×14
Drug importation policy×14
ETHIC Act×14
FDA Modernization×14
FDA policy×14
International intellectual property and market access policy×14
Issues 340B drug discount program policy×14
Medicaid rebate policy×14
Medicare rebate policy×14
Modernizing and Ensuring PBM Accountability×14
Orphan Drug Act×14
Part B policy×14
Part D redesign and policy×14
Patent eligibility policy×14
Patent submission policy×14
Patent thicket policy×14
Post-grant proceeding policy×14
Prescription Drug Pricing Policy×14
Pricing and reimbursement policy×14
Skinny Labels×14
Vaccine policy×14
WTO TRIPS waiver policy×14
Biosimilar Red Tape Elimination Act×13
Medication Affordability and Patent Integrity Act×13
Res. 566: Providing for consideration of the Senate amendment to the bill×13
Biosimilars Access and Affordability Act×12
Drug Pricing and Access×12
General Medicare and Medicaid Issues×12
IRA price negotiation expansion policy×12
Issues 340B rebate pilot program Patient assistance program policy×12
MAHA Commission Report×12
Make Our Children Healthy Again Competition policy×12
Pharmaceutical Supply Chain×12
Pharmacy Benefit Managers×12
Stopping Pharmas Ripoffs and Drug Savings For All Act×12
340B drug discount program×11
Advise and advocate on clients behalf regarding ongoing public policy×11
Antimicrobial resistance policy×11
Biopharmaceutical innovation and patent policy×11
General issues×11
General representation×11
GENErating cost Reductions for U.S×11
Importation of biopharmaceuticals×11
International pharmaceutical supply chain×11
Legislative Branch×11
Legislative issues×11
Medicare Against Rising Drugs Costs×11
Medicare Part B reimbursement×11
Merchant rights×11
Mikaela Naylon Give Kids a Chance Act×11
Pandemic and All-Hazards Preparedness Act×11
Part D changes×11
Patent fee policy×11
Patent rights×11
Prescription drug payment reform. 340B issues×11
Prescription Pricing for the People Act×11
PREVAIL Act×11
TRICARE Pharmacy Program×11
US-UK Framework Agreement×11
Valued-Based Payments×11
Access and reimbursement in Medicare Parts B and D×10
Around drug pricing×10
Biopharmaceutical patent policy×10
CLEAR LABELS Act×10
CMMI Drug Pricing Demonstration Programs×10
CMMI, and Medicare Part D×10
Consolidated Appropriations Act, 2026×10
Energy and Water Development×10
FAIR ACT×10
FY2027 Agriculture×10
FY2027 Departments of Labor×10
Government funding policy×10
Health and Human Services, and Education, and Related Agencies Appropriations×10
Intellectual property protections and enforcement×10
Medicare and healthcare policy×10
Military Construction and Veterans Affairs, and Extensions Act, 2026×10
Most Favored Patients Act×10
National security issues×10
PL 119-75×10
Protecting Patient Access to Cancer and Complex Therapies Act×10
Public Law 119-21: One Big Beautiful Bill Act×10
Section 232 tariff investigation on branded pharmaceuticals×10
SECURE Rx Act×10
Support for EPIC Act×10
Advocate on issues×8
FDA regulations, and healthcare×8
General education about policies×8
Impacting pharmaceutical development, approval and reimbursement×8
Importation of Drugs×8
Importation. 340B Program×8
Medicare Part D×8
Rebates for Medicare Part D×8
Supply chain management×8
Affordability and patient access issues×4
Antimicrobial resistance×4
Drug Premium Stabilization Program×4
Federal budget issues×4
Impacting Medicare Part D×4
Impacting pharmaceutical development×4
IP Protections related to trade agreements×4
IPI drug pricing proposal×4
IRA maximum fair price×4
Legislative proposals related to WTO TRIPS Waiver×4
Medicare IRA implementation×4
Medicare Part B Issues×4
Medicare Rebate Rule×4
Part B and 340 B programs×4
Potential tariff actions under Section 232 of the Trade Act×4
Prescription drug pricing issues, particularly related to MFN×4
User fee issues×4
Give Kids a Chance Act×3
Patent use codes policy×3
Science, and Related Agencies Appropriations Act, 2026×3
Accelerated approval policy×2
Competition policy×2
Drug shortages policy×2
Insulin policy×2
Medicaid waiver policy×2
Patient assistance program policy×2
340B and drug pricing×1
All bio-pharmaceutical related provisions×1
Biopharmaceutical issues×1
Color of Gastrointestinal Illnesses×1
DRUG Act×1
Drug pricing reform×1
Expedited Acccess to Biosimilars Act×1
Full-Year Continuing Appropriations and Extensions Act, 2025×1
FY2024 Further Consolidated Appropriations Act×1
FY2025 Budget Reconciliation Process×1
FY2025 Budget Resolution×1
General health care coverage and reimbursement for prescription drugs×1
General health care issues×1
Innovation in Pediatric Drugs Act×1
Insulin price cap×1
International reference pricing×1
IRA implementation×1
Lower Costs×1
MAPS Act×1
Market access issues×1
Military Construction×1
Monitored issues×1
More Transparency Act×1
MVP Act×1
Open Payments Expansion Act×1
Orphan Cures Act×1
Pandemic preparedness policy×1
PBM oversight×1
Pharmacy Benefit Manager×1
Prescription drug payment reform×1
Prescription Information Modernization×1
Protecting Patients from Deceptive Drug Ads Act×1
Realted to anti-competitive tactics in the pharmaceutical marketplace×1
Rx oversight×1
Saving Seniors Money on Prescriptions Act×1
Share the Savings with Seniors Act×1
Tariff policy×1
Bills in Play
82Bills referenced in this org's LD-2 filing text. Frequency = how many activities reference each.
94 mentions
89 mentions
48 mentions
47 mentions
47 mentions
47 mentions
46 mentions
39 mentions
35 mentions
27 mentions
25 mentions
25 mentions
25 mentions
25 mentions
24 mentions
23 mentions
23 mentions
23 mentions
14 mentions
14 mentions
Show all 82 bills (+62 more) ▾
14 mentions
14 mentions
14 mentions
14 mentions
14 mentions
14 mentions
13 mentions
13 mentions
13 mentions
13 mentions
13 mentions
13 mentions
13 mentions
13 mentions
13 mentions
12 mentions
12 mentions
12 mentions
12 mentions
12 mentions
12 mentions
12 mentions
12 mentions
12 mentions
12 mentions
12 mentions
11 mentions
11 mentions
11 mentions
11 mentions
11 mentions
11 mentions
11 mentions
10 mentions
10 mentions
10 mentions
10 mentions
4 mentions
2 mentions
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
Lobbyists on Record
142RAGHAV AGGARWAL · Bgr Government Affairsformer Health Insurance Specialist, CMS; Senior Health…
SALIM ALAMEDDIN · Crossroads Strategies, LLCformer Legislative Asst/Legislative Aide, Rep. Will Hu…
MEREDITH ALLISON · Pharmaceutical Research and Manufacturers of Americaformer Intern - Senator Richard Burr; Intern - Senator…
JOEL BAILEY · Bgr Government Affairsformer COS Rep. Panetta; LD Rep. Ashford; LD Rep. Math…
KRISTEN BAUTZ · Farragut Partners LLPformer Senior Advisor and Special Projects Coordinator…
ERIC BERGREN · Todd Strategy Groupformer Chief of Staff, Rep. Brett Guthrie; Staff Assis…
ALEXA BRANSON · Pharmaceutical Research and Manufacturers of Americaformer Special Asst. - White House, EOP, Offc. of Publ…
WALLY BURNETT · Crossroads Strategies, LLCformer Clerk, Senate Appropriations Committee
RICHARD BURR · Dla Piper LLP (US)former U.S. Senator
JEFFREY CARROLL · Capitol Counsel LLCformer Staff Director House Energy and Commerce Commit…
PARICK CARROLL · Tarplin, Downs & Young, LLCformer Leg Asst. Rep. Ray LaHood, Leg Dir. Rep. Kevin …
KELLY CHILDRESS LANGE · East End Group, LLCformer Rep. Rogers, Health Policy Advisor; Rep. Shimku…
+ 130 more lobbyists on record